Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III trial of Inecalcitol in patients with chronic lymphocytic leukaemia

Trial Profile

Phase III trial of Inecalcitol in patients with chronic lymphocytic leukaemia

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inecalcitol (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 12 Feb 2014 New trial record
    • 28 Jan 2014 Inecalcitrol has been designated as an orphan drug for chronic lymphocytic leukaemia in Europe, giving access to the COMP Protocol Assistance procedure to design this phase III study, according to a Hybrigenics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top